Filing Flows › Comparisons › BCYC vs KPTI
Bicycle Therapeutics vs Karyopharm Therapeutics: BCYC and KPTI compared
Bicycle Therapeutics is the larger company: $34.1M of revenue in its latest quarter (Q3 2026) against $33.4M for Karyopharm Therapeutics (Q2 2026). Bicycle Therapeutics is growing faster (+190% against -12% a year earlier). Bicycle Therapeutics is more profitable, with an operating margin of -39.6% against -67.4%.
Where the money goes: BCYC and KPTI
Bicycle Therapeutics (BCYC) · Q3 2026
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart follows the revenue to costs, profit and cash.
Karyopharm Therapeutics (KPTI) · Q2 2026
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
| Bicycle Therapeutics (BCYC) | Karyopharm Therapeutics (KPTI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $34.1M | $33.4M |
| Revenue growth, Y/Y | +190% | -12% |
| Operating margin | -39.6% | -67.4% |
| Net earnings | −$10.5M | −$67.0M |
| Net margin | -30.8% | -200.5% |
| Operating cash flow | −$40.3M | −$24.9M |
Where the revenue comes from
Karyopharm Therapeutics
- Product: $30.8M (92%)
- License and Other: $2.7M (8%)
Questions
Which is bigger, Bicycle Therapeutics or Karyopharm Therapeutics?
Bicycle Therapeutics is the larger company: $34.1M of revenue in its latest quarter (Q3 2026) against $33.4M for Karyopharm Therapeutics (Q2 2026).
Is Bicycle Therapeutics or Karyopharm Therapeutics growing faster?
Bicycle Therapeutics is growing faster (+190% against -12% a year earlier).
Which is more profitable, Bicycle Therapeutics or Karyopharm Therapeutics?
Bicycle Therapeutics is more profitable, with an operating margin of -39.6% against -67.4%.
More: Bicycle Therapeutics earnings · how Bicycle Therapeutics makes money · Karyopharm Therapeutics earnings · how Karyopharm Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.